TCL Archive McGivney Out at NCCN as Board Cites Management Style, Strategic Direction January 13, 2012
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive New Treatment Approaches For A Variety Of Leukemias Described At ASH Meeting January 30, 2004